Across TCGA pan-cancer cohorts, STK39 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK39 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STK39 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STK39 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where STK39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.693	0.922	.006	23	view →
HNSC	DFS	Quartile	II,III,IV	0.908	0.720	.007	15	view →
PDAC	OS	Median	IV	0.381	0.951	.006	9	view →
LUAD	OS	Quartile	II,III,IV	0.771	0.434	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: STK39 tumor-vs-normal RNA expression · all STK39 data types